Mallinckrodt (Mallinckrodt) Additional Paid-In Capital : $1,197 Mil(As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Mallinckrodt Additional Paid-In Capital?

Mallinckrodt's quarterly additional paid-in capital increased from Jun. 2023 ($2,196 Mil) to Sep. 2023 ($2,199 Mil) but then stayed the same from Sep. 2023 ($2,199 Mil) to Mar. 2024 ($1,197 Mil).

Mallinckrodt's annual additional paid-in capital increased from Dec. 2020 ($5,588 Mil) to Dec. 2021 ($5,598 Mil) but then declined from Dec. 2021 ($5,598 Mil) to Dec. 2022 ($2,191 Mil).

Mallinckrodt Additional Paid-In Capital Historical Data

The historical data trend for Mallinckrodt's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mallinckrodt Additional Paid-In Capital Chart

Mallinckrodt Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Additional Paid-In Capital

Get a 7-Day Free Trial

5,528.20

5,562.50

5,587.60

5,597.80

2,191.00

Mallinckrodt Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															2,191.00	2,193.60	2,196.10	2,198.50	1,196.50

Mallinckrodt Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Mallinckrodt Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Mallinckrodt's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Mallinckrodt (Mallinckrodt) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mallinckrodt PLC (OTCPK:MCKPF) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, IRL, 15

Website

https://www.mallinckrodt.com

Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.

Executives

Alta Fundamental Advisers Llc	10 percent owner	1500 BROADWAY, SUITE 704, NEW YORK NY 10036
Jason Daniel Goodson	officer: EVP & Head of Corp Development	106 CENTRAL PARK AVENUE, WENTZVILLE MO 63885
James R Sulat	director
Paul Bisaro	director
Sigurdur O Olafsson	director, officer: President and CEO	360 MOUNT KEMBLE AVENUE, MORRISTOWN NJ 07960
Stephen Andrew Welch	officer: EVP & Head of Spec Generics	18440 BRIDGEMORE LANE, LOUISVILLE KY 40245
Peter C Richardson	officer: EVP & Chief Scientific Officer	28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Susan Michele Silbermann	director	C/O LIANBIO, 103 CARNEGIE CENTER DRIVE, SUITE 215, PRINCETON NJ 08540
Lisa French	officer: EVP & Chief Commercial Officer	301 CONTINENTAL LANE, PAOLI PA 19301
Mark Anthony Tyndall	officer: EVP & Chief Legal Offi & Secre	1101 Q ST NW, WASHINGTON DC 20009
Henriette Nielsen	officer: EVP & Chief Transformation OFC	202 WEST 85TH STREET, APT. 5, NEW YORK NY 10024
Karen Ling	director	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Anne Clem Whitaker	director	109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
Olifant Luxco S.a R.l.	10 percent owner	19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Paul Rutherford Carter	director	SOUTH BUILDING, 2 ROUNDWOOD AVENUE, STOCKLEY PARK X0 UB11 1AF